Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSS | P25774 | 1/20 | 0.33 |
| ▸ | CTSK | P43235 | 1/20 | 0.33 |
| ▸ | AR | P10275 | 1/20 | 0.33 |
| ▸ | TACR1 | P25103 | 1/20 | 0.32 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.31 |
| ▸ | HTR2A | P28223 | 1/20 | 0.31 |
| ▸ | HTR2C | P28335 | 1/20 | 0.31 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.31 |
| ▸ | HTR2B | P41595 | 1/20 | 0.31 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
| ▸ | NMT1 | P30419 | 1/20 | 0.30 |
| ▸ | PPARG | P37231 | 1/20 | 0.30 |
| ▸ | PPARA | Q07869 | 1/20 | 0.30 |
| ▸ | XDH | P47989 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18004907 | 0.87 | GRM5 (0.34) | CHEK1HTR2AHTR2CSLC6A4HTR2B | |
| SCHEMBL18006195 | 0.86 | PPARG (0.42) | MAPTPPARGPPARA | |
| SCHEMBL18006188 | 0.84 | RHOC (0.43) | PPARGPPARA | |
| SCHEMBL18006245 | 0.83 | PRMT6 (0.42) | CTSSCTSKMAPT | |
| SCHEMBL18006221 | 0.83 | KDM4E (0.40) | SLC6A4MAPTPPARGPPARA | |
| SCHEMBL18006412 | 0.82 | CHEK1 (0.42) | CHEK1HTR2AHTR2CSLC6A4HTR2B | |
| SCHEMBL18006207 | 0.81 | POLB (0.33) | CTSSCTSK | |
| SCHEMBL18004083 | 0.80 | SOD1 (0.37) | CTSSCTSKTACR1XDH | |
| SCHEMBL18004910 | 0.79 | CYP11B1 (0.41) | CTSSCTSKTACR1CHEK1HTR2A | |
| SCHEMBL18003800 | 0.79 | ALDH1A1 (0.35) | CTSSCTSKMAPTXDH |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4219477-A1 | CYANOTRIAZOLE COMPOUNDS | Otsuka Pharmaceutical Co., Ltd. (JP) | 2023-08-02 | — | — | EP | disclosed |
| US-10626095-B2 | Cyanotriazole compounds | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2020-04-21 | — | — | US | disclosed |
| US-20160229816-A1 | CYANOTRIAZOLE COMPOUNDS | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2016-08-11 | — | — | US | disclosed |
| US-20160229816-A1 | CYANOTRIAZOLE COMPOUNDS | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2016-08-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10626095-B2 | Cyanotriazole compounds | CS, PC, ACAT1 | CTSS 2273/4885CTSK 2390/4885AR 3449/4885 |
| US-20160229816-A1 | CYANOTRIAZOLE COMPOUNDS | CS, PC, ACAT1 | CTSS 2273/4885CTSK 2390/4885AR 3449/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.